Want to see HK:9939 full AI Analyst Report?
9939 Stock Chart & Stats
HK$1.69
-HK$0.05(-2.92%)
At close: 4:00 PM EDT
HK$1.69
-HK$0.05(-2.92%)
Day’s Range― - ―
52-Week RangeHK$1.61 - HK$4.70
Previous CloseN/A
Volume72.50K
Average Volume (3M)4.99M
Market Cap
HK$835.46M
Enterprise ValueHK$962.61
Total Cash (Recent Filing)HK$34.78M
Total Debt (Recent Filing)HK$86.64M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding498,660,100
10 Day Avg. Volume2,605,850
30 Day Avg. Volume4,990,601
Financial Highlights & Ratios
PEG Ratio-0.18
Price to Book (P/B)4.33
Price to Sales (P/S)24.23
P/FCF Ratio-4.77
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
R&D-focused Business Model And Monetization PathwaysKintor's core model is durable for a clinical-stage biotech: advancing proprietary candidates while targeting out-licensing, milestone payments and eventual commercialization. This reduces reliance on immediate product sales and creates scalable future revenue if candidates progress and partners are secured.
Recent Revenue ReboundA strong revenue rebound signals improving cash inflows, possibly from milestones, licensing or one-time receipts tied to pipeline progress. Sustained higher revenue would lengthen runway, reduce near-term financing needs and validate development progress versus prior years of decline.
Moderate Financial LeverageDebt levels are not excessive for a biotech, which preserves financial flexibility during development cycles. Moderate leverage reduces immediate solvency pressure, making it easier to raise incremental capital or restructure financing without severe near-term default risk if cash burn is managed.
Bears Say
Negative Gross Profit And Entrenched LossesPersistent negative gross profit indicates the company has not yet achieved core product-level economics and is likely not generating recurring product sales. For a biotech, this underscores lengthy commercialization timelines and shows core operations are not covering direct costs, prolonging reliance on financing.
Consistent Negative Operating And Free Cash FlowSustained negative operating and free cash flow reflect ongoing cash burn from R&D and operations. This is a durable constraint: without a material change in cash generation or successful partner payments, the company will remain dependent on external capital, which can dilute shareholders and add execution risk.
Shrinking Assets And Shareholders' EquityMaterial declines in assets and equity signal value erosion from cumulative losses or financing terms that weaken stakeholders. Over time this reduces balance sheet resilience, limits collateral for borrowing, and raises funding cost and difficulty — a structural weakness if losses persist.
Kintor Pharmaceutical Ltd News
9939 FAQ
What was Kintor Pharmaceutical Ltd’s price range in the past 12 months?
Kintor Pharmaceutical Ltd lowest stock price was HK$1.60 and its highest was HK$4.70 in the past 12 months.
What is Kintor Pharmaceutical Ltd’s market cap?
Kintor Pharmaceutical Ltd’s market cap is HK$835.46M.
When is Kintor Pharmaceutical Ltd’s upcoming earnings report date?
Kintor Pharmaceutical Ltd’s upcoming earnings report date is Aug 19, 2026 which is in 12 days.
How were Kintor Pharmaceutical Ltd’s earnings last quarter?
Kintor Pharmaceutical Ltd released its earnings results on Mar 30, 2026. The company reported -HK$0.277 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kintor Pharmaceutical Ltd overvalued?
According to Wall Street analysts Kintor Pharmaceutical Ltd’s price is currently Overvalued.
Does Kintor Pharmaceutical Ltd pay dividends?
Kintor Pharmaceutical Ltd does not currently pay dividends.
What is Kintor Pharmaceutical Ltd’s EPS estimate?
Kintor Pharmaceutical Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kintor Pharmaceutical Ltd have?
Kintor Pharmaceutical Ltd has 498,660,100 shares outstanding.
What happened to Kintor Pharmaceutical Ltd’s price movement after its last earnings report?
Kintor Pharmaceutical Ltd reported an EPS of -HK$0.277 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.216%.
Which hedge fund is a major shareholder of Kintor Pharmaceutical Ltd?
Currently, no hedge funds are holding shares in HK:9939
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kintor Pharmaceutical Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-30.76%
Trailing 12-Months
Company Description
Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited, a biotechnology firm in its clinical development phase, is dedicated to the discovery, advancement, and marketing of a diverse array of small molecule and biological therapies. The company primarily concentrates on androgen-receptor-related diseases that represent significant unmet medical needs, serving patients both in the People's Republic of China and globally. Its comprehensive pipeline of investigational products includes: Proxalutamide, a second-generation androgen receptor (AR) antagonist, being explored for the treatment of metastatic castration-resistant prostate cancer, AR-positive breast cancer, and COVID-19. Pyrilutamide, another AR antagonist, is under development for androgenetic alopecia (AGA) and acne vulgaris. An ALK-1 antibody targeting metastatic hepatocellular carcinoma (HCC) and various other solid tumors. GT20029, a topical AR-PROTAC compound, designed to address AGA and acne vulgaris. The dual-target antibody PD-L1/TGF-ß, intended for non-small cell lung cancer, biliary tract cancer, triple-negative breast cancer, and HPV-associated tumors. Detorsertib, which is being investigated for metastatic solid tumors such as breast cancer, prostate cancer, and HCC. A Hedgehog/SMO Inhibitor, an agent that blocks the hedgehog signal transduction pathway, aimed at treating blood cancer and basal-cell carcinoma. Founded in 2009, Kintor Pharmaceutical Limited is headquartered in Suzhou, People's Republic of China.
Technical Analysis
Alphamab Oncology
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
3D Medicines, Inc.
―
CARsgen Therapeutics Holdings Ltd.
―
Ascentage Pharma Group International
―